ATXS
Income statement / Annual
Last year (2023), Astria Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Astria Therapeutics, Inc.'s net income was -$72.89 M.
See Astria Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$500,000.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$26,000.00 |
$119,000.00 |
$0.00 |
$395,000.00 |
$202,000.00 |
$0.00 |
| Gross Profit |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
-$26,000.00 |
-$119,000.00 |
$500,000.00 |
-$395,000.00 |
-$202,000.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
| Research and Development
Expenses |
$57.33 M
|
$34.26 M
|
$15.55 M
|
$25.59 M
|
$18.32 M
|
$17.04 M
|
$18.68 M
|
$25.45 M
|
$23.03 M
|
$15.69 M
|
| General & Administrative
Expenses |
$25.70 M
|
$19.24 M
|
$14.81 M
|
$11.85 M
|
$8.77 M
|
$9.33 M
|
$8.91 M
|
$10.11 M
|
$8.63 M
|
$6.00 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$25.70 M
|
$19.24 M
|
$14.81 M
|
$11.85 M
|
$8.77 M
|
$9.33 M
|
$8.91 M
|
$10.11 M
|
$8.63 M
|
$6.00 M
|
| Other Expenses |
$0.00 |
-$55,000.00 |
-$58,000.00 |
-$101,000.00 |
-$50,000.00 |
$176,000.00 |
$32,000.00 |
$93,000.00 |
$7,000.00 |
$3,000.00 |
| Operating Expenses |
$83.03 M |
$53.50 M |
$30.36 M |
$37.44 M |
$27.09 M |
$26.37 M |
$27.59 M |
$35.56 M |
$31.66 M |
$21.68 M |
| Cost And Expenses |
$83.03 M |
$53.50 M |
$30.36 M |
$37.44 M |
$27.09 M |
$26.37 M |
$27.59 M |
$35.56 M |
$31.66 M |
$21.68 M |
| Interest Income |
$10.20 M |
$1.72 M |
$122,000.00 |
$236,000.00 |
$845,000.00 |
$425,000.00 |
$160,000.00 |
$242,000.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
-$1.67 M |
$0.00 |
$0.00 |
$0.00 |
$100,000.00 |
$462,000.00 |
$837,000.00 |
$978,000.00 |
$206,000.00 |
| Depreciation &
Amortization |
-$15.20 M
|
$228,485.00
|
-$164.62 M
|
$26,000.00
|
$26,000.00
|
$119,000.00
|
$304,000.00
|
$395,000.00
|
$202,000.00
|
$248,000.00
|
| EBITDA |
-$83.03 M
|
-$53.50 M
|
-$194.98 M
|
-$37.44 M
|
-$26.27 M
|
-$25.65 M
|
-$26.60 M
|
-$34.83 M
|
-$31.46 M
|
-$21.43 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
-53.2 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
-54.19
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$10.14 M
|
$1.67 M
|
$64,000.00
|
$135,000.00
|
$795,000.00
|
$501,000.00
|
-$270,000.00
|
-$502,000.00
|
-$971,000.00
|
-$203,000.00
|
| Income Before Tax |
-$72.89 M |
-$51.83 M |
-$194.91 M |
-$37.30 M |
-$26.29 M |
-$25.87 M |
-$27.36 M |
-$36.06 M |
-$32.63 M |
-$21.88 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
-54.73
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
-$1.67 M |
-$164.74 M |
-$236,000.00 |
-$50,000.00 |
$601,000.00 |
$494,000.00 |
$930,000.00 |
$783,000.00 |
$209,000.00 |
| Net Income |
-$72.89 M |
-$50.17 M |
-$30.17 M |
-$37.06 M |
-$26.24 M |
-$25.87 M |
-$27.36 M |
-$36.06 M |
-$32.63 M |
-$21.88 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
-54.73 |
0 |
0 |
0 |
| EPS |
-2.42 |
-3.43 |
-3.38 |
-12.12 |
-14.06 |
-30.71 |
-75.73 |
-133.31 |
-243.45 |
-151.53 |
| EPS Diluted |
-2.42 |
-3.43 |
-3.38 |
-12.12 |
-14.06 |
-30.71 |
-75.73 |
-133.31 |
-243.45 |
-151.53 |
| Weighted Average Shares
Out |
$30.12 M
|
$14.62 M
|
$8.93 M
|
$3.06 M
|
$1.87 M
|
$842,470.00
|
$361,358.00
|
$270,503.00
|
$134,032.00
|
$144,422.00
|
| Weighted Average Shares
Out Diluted |
$30.12 M
|
$14.62 M
|
$8.93 M
|
$3.06 M
|
$1.87 M
|
$842,472.00
|
$361,359.00
|
$270,503.00
|
$134,032.00
|
$144,422.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
